{"nctId":"NCT01061736","briefTitle":"Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients","startDateStruct":{"date":"2010-03"},"conditions":["Rheumatoid Arthritis"],"count":1675,"armGroups":[{"label":"Part A: SAR 100 mg qw","type":"EXPERIMENTAL","interventionNames":["Drug: Sarilumab","Drug: Methotrexate","Drug: Folic Acid"]},{"label":"Part A: SAR 150 mg qw","type":"EXPERIMENTAL","interventionNames":["Drug: Sarilumab","Drug: Methotrexate","Drug: Folic Acid"]},{"label":"Part A: SAR 100 mg q2w","type":"EXPERIMENTAL","interventionNames":["Drug: Sarilumab","Drug: Placebo (for sarilumab)","Drug: Methotrexate","Drug: Folic Acid"]},{"label":"Part A: SAR 150 mg q2w","type":"EXPERIMENTAL","interventionNames":["Drug: Sarilumab","Drug: Placebo (for sarilumab)","Drug: Methotrexate","Drug: Folic Acid"]},{"label":"Part A: SAR 200 mg q2w","type":"EXPERIMENTAL","interventionNames":["Drug: Sarilumab","Drug: Placebo (for sarilumab)","Drug: Methotrexate","Drug: Folic Acid"]},{"label":"Part A: Placebo qw","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo (for sarilumab)","Drug: Methotrexate","Drug: Folic Acid"]},{"label":"Part B Cohort 1: Non-selected Doses","type":"EXPERIMENTAL","interventionNames":["Drug: Sarilumab","Drug: Placebo (for sarilumab)","Drug: Methotrexate","Drug: Folic Acid"]},{"label":"Part B: SAR 150 mg q2w (Cohort 1[Selected Dose]+Cohort 2)","type":"EXPERIMENTAL","interventionNames":["Drug: Sarilumab","Drug: Methotrexate","Drug: Folic Acid"]},{"label":"Part B: SAR 200 mg q2w (Cohort 1[Selected Dose]+Cohort 2)","type":"EXPERIMENTAL","interventionNames":["Drug: Sarilumab","Drug: Methotrexate","Drug: Folic Acid"]},{"label":"Part B: Placebo q2w (Cohort 1[Selected Dose]+Cohort 2)","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo (for sarilumab)","Drug: Methotrexate","Drug: Folic Acid"]}],"interventions":[{"name":"Sarilumab","otherNames":["SAR153191","REGN88"]},{"name":"Placebo (for sarilumab)","otherNames":[]},{"name":"Methotrexate","otherNames":[]},{"name":"Folic Acid","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria :\n\n* Diagnosis of rheumatoid arthritis ≥3 months duration\n* Active disease defined as:\n\n  * at least 8/68 tender joints and 6/66 swollen joints,\n  * high sensitivity C-reactive protein (hs-CRP) \\>6 mg/l,\n  * continuous treatment with MTX for at least 12 weeks prior to baseline visit and on stable dose for at least 6 weeks prior to screening visit.\n\nPart B only:\n\n* Bone erosion based on documented X-ray prior to first study drug intake, or\n* Cyclic Citrullinated Peptide (CCP) positive, or\n* Rheumatoid Factor (RF) positive.\n\nExclusion criteria:\n\n* Age \\<18 years or \\>75 years.\n* Treatment with disease-modifying antirheumatic drugs (DMARDs) other than MTX within 4 weeks or 12 weeks prior to screening (depending on DMARDs).\n* Past history of non-response to prior Tumor Necrosis Factor (TNF) or biologic treatment.\n* Any past or current biologic agents for the treatment of rheumatoid arthritis within 3 months.\n* Use of parenteral glucocorticoids or intraarticular glucocorticoids within 4 weeks prior to screening visit.\n* Use of oral glucocorticoid greater than 10mg/day or equivalent/day, or a change in dosage within 4 weeks prior to baseline visit.\n\nThe above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Part A: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12","description":"ACR20 response was defined, based on guidelines set forth by the American College of Rheumatology (ACR), as ≥20 % improvement in tender joint count and swollen joint count as well as ≥20% improvement in at least 3 of 5 following measures: C-Reactive Protein (CRP), Participant assessment of pain; Participant's global assessment of disease activity; Physician global assessment of disease activity; and Health Assessment Question-Disability Index (HAQ-DI). Missing data imputed by Last Observation Carried Forward (LOCF).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"72","spread":null},{"groupId":"OG002","value":"49","spread":null},{"groupId":"OG003","value":"66.7","spread":null},{"groupId":"OG004","value":"65.4","spread":null},{"groupId":"OG005","value":"46.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Part B: Percentage of Participants Achieving ACR20 Response at Week 24","description":"ACR20 improvement responses were determined without imputation of missing post-baseline values. In addition data collected after treatment discontinuation or rescue was set to missing. Responder status was determined if possible. With these rules, participants automatically became non-responders for all time points beyond the time point they started rescue treatment or discontinued study treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"66.4","spread":null},{"groupId":"OG002","value":"33.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Part B: Change From Baseline in Health Assessment Question Disability Index (HAQ-DI) at Week 16","description":"HAQ-DI was a participant-reported questionnaire that assesses the difficulty of performing daily activities: dress/groom, arise, eat, walk, reach, grip, hygiene and common activities. Overall score range from 0=least difficulty to 3=extreme difficulty. An increase in the score indicates a worsening of physical function while a decrease in the score represents improvement. Data collected after treatment discontinuation was set to missing.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.63","spread":"0.63"},{"groupId":"OG001","value":"1.69","spread":"0.63"},{"groupId":"OG002","value":"1.61","spread":"0.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.08","spread":"0.67"},{"groupId":"OG001","value":"1.11","spread":"0.7"},{"groupId":"OG002","value":"1.31","spread":"0.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.54","spread":"0.55"},{"groupId":"OG001","value":"-0.58","spread":"0.63"},{"groupId":"OG002","value":"-0.3","spread":"0.58"}]}]}]},{"type":"PRIMARY","title":"Part B: Change From Baseline in Van Der Heijde Modified Total Sharp Score (mTSS) at Week 52","description":"The Sharp method modified by D. van der Heijde involves separate scores for erosions and joint space narrowing based on radiographs to assess the degree of structural damage. Total score range from 0 (normal) to 448 (worst possible total score). An increase in total score represents progression of structural damage. Missing data were imputed by the linear extrapolation method.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.67","spread":"63.42"},{"groupId":"OG001","value":"46.34","spread":"57.43"},{"groupId":"OG002","value":"48.01","spread":"65.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.57","spread":"63.73"},{"groupId":"OG001","value":"46.59","spread":"57.63"},{"groupId":"OG002","value":"50.79","spread":"65.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.90","spread":"4.66"},{"groupId":"OG001","value":"0.25","spread":"4.61"},{"groupId":"OG002","value":"2.78","spread":"7.73"}]}]}]},{"type":"SECONDARY","title":"Part B: Percentage of Participants Achieving a Major Clinical Response at Week 52","description":"Major clinical response was defined as an ACR70 response maintained for at least 24 consecutive weeks. ACR70 response uses the same criteria as for ACR20 but requires 70% improvement. In the primary approach, data collected after treatment discontinuation or rescue was set to missing. No imputation of missing post-baseline values was performed. Responder status was determined if possible. With these rules, participants automatically became non-responders for all time points beyond the time point they started rescue treatment or discontinued study treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.8","spread":null},{"groupId":"OG001","value":"14.8","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":50},"commonTop":["Neutropenia","Upper respiratory tract infection","Accidental overdose","Alanine aminotransferase increased","Nasopharyngitis"]}}}